🏛️ Verified NIH Record • Updated 2026-07-15

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE) (NCT05592938)

Partial Breast Re-irradiation Using Ultra Hypofractionation: Phase 2 Multi-institutional Study (PRESERVE)

🟢 Recruiting Observational / Diagnostic 📋 Clinical Research Protocol Sponsor: University Health Network, Toronto

🩺 Plain-English Summary (8th-Grade Level)

Breast-conserving surgery followed by re-irradiation with partial breast irradiation (rPBI) has recently been found to be a safe alternative to mastectomy for women who have undergone prior whole breast radiation. By reducing the volume of tissue receiving radiation, rPBI has been associated with less toxicity and improved cosmetic outcomes. For many women with early-stage breast cancer, shorter 1-week (5-fraction) courses of breast radiation (ultra-fractionation) have been found to be equivalent to longer fractionation schedules in the upfront treatment setting. These 1-week schedules are more convenient for patients, with fewer treatments and shorter overall treatment time. The investigators hypothesize that a 1-week ultra-hypofractionated rPBI regimen following breast-conserving surgery (BCS) for local recurrence or new primary breast cancer in the previously irradiated breast (LR) will be associated with acceptable toxicity at 1 year (\<13% grade \>3 toxicity).

Who can join: Review the eligibility criteria below.

Location: NYU Langone Health — New York, New York

Age range: 18 Years to 99 Years

🧪 Interventions in This Study

  • rPBI (RADIATION)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (19 Sites)

  • NYU Langone Health — New York, New York
  • Columbia University Medical Center — New York, New York
  • Virgina Community University Massey Comprehensive Cancer Center — Richmond, Virginia
  • Peter MacCallum Cancer Centre — Melbourne, Victoria
  • A.C.Camargo Cancer Center — São Paulo, São Paulo
  • Royal Victoria Regional Health Centre — Barrie, Ontario
  • London Health Science Centre - Verspeeten Family Cancer Centre — London, Ontario
  • Lakeridge Health — Oshawa, Ontario
  • Odette Cancer Centre — Toronto, Ontario
  • Princess Margaret Cancer Centre — Toronto, Ontario
  • CHU de Québec-Université Laval — Montreal, Quebec
  • Hôpital Maisonneuve-Rosemont - CIUSSS de l'Est-de-l'Île-de-Montréal — Montreal, Quebec
  • Centre hospitalier de l'Université de Montréal — Montreal, Quebec
  • Clinica IRAM — Vitacura, Santiago Metropolitan
  • Tel-Aviv Sourasky Medical Centre — Tel Aviv,
  • AOU Careggi - Florence University Hospital — Florence,
  • King Hussein Cancer Centre — Amman, Jordan
  • The Aga Khan University — Nairobi,
  • Universitiy Malaya Medical Centre — Kuala Lumpur,

📞 Contact the Study Coordinator

Phone: (416) 946-6513

Email: danielle.rodin@uhn.ca

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Breast Cancer

Explore by condition: All Breast Cancer clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗